Go Pro

Teladoc Health (TDOC) Competitors

Teladoc Health logo
$6.46 0.00 (0.00%)
As of 09/3/2026 03:58 PM Eastern

TDOC vs. AMZN, CRSP, ROKU, ZM, and AMWL

Should you buy Teladoc Health stock or one of its competitors? Teladoc Health's main competitors and comparable companies include Amazon.com (AMZN), CRISPR Therapeutics (CRSP), Roku (ROKU), Zoom Communications (ZM), and American Well (AMWL). Companies are selected based on similarities in market, industry, and size.

How does Teladoc Health compare to Amazon.com?

Amazon.com (NASDAQ:AMZN) and Teladoc Health (NYSE:TDOC) are related companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

Amazon.com has higher revenue and earnings than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than Amazon.com, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amazon.com$716.92B3.90$77.67B$12.4320.83
Teladoc Health$2.53B0.46-$200.32M-$0.99N/A

Amazon.com currently has a consensus target price of $323.26, indicating a potential upside of 24.86%. Teladoc Health has a consensus target price of $7.54, indicating a potential upside of 16.65%. Given Amazon.com's stronger consensus rating and higher probable upside, equities analysts plainly believe Amazon.com is more favorable than Teladoc Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amazon.com
0 Sell rating(s)
2 Hold rating(s)
56 Buy rating(s)
1 Strong Buy rating(s)
2.98
Teladoc Health
1 Sell rating(s)
10 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.25

72.2% of Amazon.com shares are held by institutional investors. Comparatively, 76.8% of Teladoc Health shares are held by institutional investors. 8.9% of Amazon.com shares are held by company insiders. Comparatively, 0.7% of Teladoc Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Amazon.com had 247 more articles in the media than Teladoc Health. MarketBeat recorded 262 mentions for Amazon.com and 15 mentions for Teladoc Health. Amazon.com's average media sentiment score of 0.78 beat Teladoc Health's score of 0.49 indicating that Amazon.com is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amazon.com
144 Very Positive mention(s)
39 Positive mention(s)
33 Neutral mention(s)
33 Negative mention(s)
11 Very Negative mention(s)
Positive
Teladoc Health
8 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Amazon.com has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market. Comparatively, Teladoc Health has a beta of 2.12, indicating that its share price is 112% more volatile than the broader market.

Amazon.com has a net margin of 17.44% compared to Teladoc Health's net margin of -7.13%. Amazon.com's return on equity of 18.00% beat Teladoc Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Amazon.com17.44% 18.00% 8.97%
Teladoc Health -7.13%-12.15%-5.83%

Summary

Amazon.com beats Teladoc Health on 15 of the 17 factors compared between the two stocks.

How does Teladoc Health compare to CRISPR Therapeutics?

Teladoc Health (NYSE:TDOC) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

76.8% of Teladoc Health shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 0.7% of Teladoc Health shares are owned by company insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Teladoc Health has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Teladoc Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teladoc Health$2.53B0.46-$200.32M-$0.99N/A
CRISPR Therapeutics$3.51M1,556.13-$581.60M-$4.76N/A

Teladoc Health has a net margin of -7.13% compared to CRISPR Therapeutics' net margin of -3,368.72%. Teladoc Health's return on equity of -12.15% beat CRISPR Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Teladoc Health-7.13% -12.15% -5.83%
CRISPR Therapeutics -3,368.72%-24.39%-18.25%

Teladoc Health has a beta of 2.12, meaning that its share price is 112% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market.

In the previous week, Teladoc Health had 2 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 15 mentions for Teladoc Health and 13 mentions for CRISPR Therapeutics. Teladoc Health's average media sentiment score of 0.49 beat CRISPR Therapeutics' score of 0.36 indicating that Teladoc Health is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teladoc Health
8 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
CRISPR Therapeutics
1 Very Positive mention(s)
4 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Teladoc Health presently has a consensus target price of $7.54, suggesting a potential upside of 16.65%. CRISPR Therapeutics has a consensus target price of $68.06, suggesting a potential upside of 20.47%. Given CRISPR Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CRISPR Therapeutics is more favorable than Teladoc Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teladoc Health
1 Sell rating(s)
10 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.25
CRISPR Therapeutics
1 Sell rating(s)
6 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.61

Summary

Teladoc Health beats CRISPR Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Teladoc Health compare to Roku?

Roku (NASDAQ:ROKU) and Teladoc Health (NYSE:TDOC) are related companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

Roku has a net margin of 6.82% compared to Teladoc Health's net margin of -7.13%. Roku's return on equity of 13.73% beat Teladoc Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Roku6.82% 13.73% 8.34%
Teladoc Health -7.13%-12.15%-5.83%

Roku has higher revenue and earnings than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than Roku, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Roku$4.74B4.96$88.36M$2.3467.65
Teladoc Health$2.53B0.46-$200.32M-$0.99N/A

Roku has a beta of 2.05, suggesting that its stock price is 105% more volatile than the broader market. Comparatively, Teladoc Health has a beta of 2.12, suggesting that its stock price is 112% more volatile than the broader market.

In the previous week, Roku had 19 more articles in the media than Teladoc Health. MarketBeat recorded 34 mentions for Roku and 15 mentions for Teladoc Health. Teladoc Health's average media sentiment score of 0.49 beat Roku's score of 0.39 indicating that Teladoc Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Roku
15 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral
Teladoc Health
8 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Roku presently has a consensus price target of $156.17, indicating a potential downside of 1.35%. Teladoc Health has a consensus price target of $7.54, indicating a potential upside of 16.65%. Given Teladoc Health's higher probable upside, analysts plainly believe Teladoc Health is more favorable than Roku.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Roku
0 Sell rating(s)
19 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.33
Teladoc Health
1 Sell rating(s)
10 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.25

86.3% of Roku shares are owned by institutional investors. Comparatively, 76.8% of Teladoc Health shares are owned by institutional investors. 13.5% of Roku shares are owned by insiders. Comparatively, 0.7% of Teladoc Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Roku beats Teladoc Health on 14 of the 17 factors compared between the two stocks.

How does Teladoc Health compare to Zoom Communications?

Zoom Communications (NASDAQ:ZM) and Teladoc Health (NYSE:TDOC) are related companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

Zoom Communications currently has a consensus target price of $112.55, indicating a potential upside of 14.68%. Teladoc Health has a consensus target price of $7.54, indicating a potential upside of 16.65%. Given Teladoc Health's higher probable upside, analysts plainly believe Teladoc Health is more favorable than Zoom Communications.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zoom Communications
0 Sell rating(s)
12 Hold rating(s)
16 Buy rating(s)
0 Strong Buy rating(s)
2.57
Teladoc Health
1 Sell rating(s)
10 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.25

In the previous week, Zoom Communications had 4 more articles in the media than Teladoc Health. MarketBeat recorded 19 mentions for Zoom Communications and 15 mentions for Teladoc Health. Zoom Communications' average media sentiment score of 0.84 beat Teladoc Health's score of 0.49 indicating that Zoom Communications is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zoom Communications
8 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Teladoc Health
8 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Zoom Communications has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, Teladoc Health has a beta of 2.12, meaning that its share price is 112% more volatile than the broader market.

Zoom Communications has a net margin of 65.19% compared to Teladoc Health's net margin of -7.13%. Zoom Communications' return on equity of 10.86% beat Teladoc Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Zoom Communications65.19% 10.86% 8.93%
Teladoc Health -7.13%-12.15%-5.83%

66.5% of Zoom Communications shares are held by institutional investors. Comparatively, 76.8% of Teladoc Health shares are held by institutional investors. 8.8% of Zoom Communications shares are held by company insiders. Comparatively, 0.7% of Teladoc Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Zoom Communications has higher revenue and earnings than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than Zoom Communications, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zoom Communications$4.87B5.91$1.90B$10.809.09
Teladoc Health$2.53B0.46-$200.32M-$0.99N/A

Summary

Zoom Communications beats Teladoc Health on 13 of the 16 factors compared between the two stocks.

How does Teladoc Health compare to American Well?

Teladoc Health (NYSE:TDOC) and American Well (NYSE:AMWL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

In the previous week, Teladoc Health had 10 more articles in the media than American Well. MarketBeat recorded 15 mentions for Teladoc Health and 5 mentions for American Well. Teladoc Health's average media sentiment score of 0.49 beat American Well's score of 0.00 indicating that Teladoc Health is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teladoc Health
8 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
American Well
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Teladoc Health currently has a consensus target price of $7.54, indicating a potential upside of 16.65%. American Well has a consensus target price of $9.50, indicating a potential downside of 28.46%. Given Teladoc Health's stronger consensus rating and higher possible upside, research analysts plainly believe Teladoc Health is more favorable than American Well.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teladoc Health
1 Sell rating(s)
10 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.25
American Well
1 Sell rating(s)
5 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Teladoc Health has a net margin of -7.13% compared to American Well's net margin of -35.75%. Teladoc Health's return on equity of -12.15% beat American Well's return on equity.

Company Net Margins Return on Equity Return on Assets
Teladoc Health-7.13% -12.15% -5.83%
American Well -35.75%-30.12%-22.30%

Teladoc Health has a beta of 2.12, meaning that its stock price is 112% more volatile than the broader market. Comparatively, American Well has a beta of 1.71, meaning that its stock price is 71% more volatile than the broader market.

American Well has lower revenue, but higher earnings than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than American Well, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teladoc Health$2.53B0.46-$200.32M-$0.99N/A
American Well$249.32M0.88-$95.70M-$4.77N/A

76.8% of Teladoc Health shares are held by institutional investors. Comparatively, 56.1% of American Well shares are held by institutional investors. 0.7% of Teladoc Health shares are held by insiders. Comparatively, 12.8% of American Well shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Teladoc Health beats American Well on 12 of the 16 factors compared between the two stocks.

Get Teladoc Health News Delivered to You Automatically

Sign up to receive the latest news and ratings for TDOC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TDOC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TDOC vs. The Competition

MetricTeladoc HealthHealthcare Technology IndustryHealthcare SectorNYSE Exchange
Market Cap$1.17B$1.76B$7.26B$23.50B
Dividend YieldN/A4.70%2.53%3.73%
P/E Ratio-6.5321.24273.2929.39
Price / Sales0.4683.99613.4520.99
Price / Cash3.5931.8777.8232.15
Price / Book0.907.3512.897.63
Net Income-$200.32M-$26.60M$3.47B$1.07B
7 Day Performance-0.77%-0.13%0.60%-0.16%
1 Month Performance-3.93%10.97%5.73%-0.46%
1 Year Performance-15.50%-15.06%25.35%13.09%

Teladoc Health Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TDOC
Teladoc Health
2.746 of 5 stars
$6.46
flat
$7.54
+16.7%
-16.8%$1.17B$2.53BN/A5,600
AMZN
Amazon.com
4.8543 of 5 stars
$262.07
+1.3%
$322.39
+23.0%
+14.6%$2.83T$775.68B21.081,576,000
CRSP
CRISPR Therapeutics
2.4106 of 5 stars
$57.08
-4.1%
$68.06
+19.2%
+6.6%$5.52B$3.51MN/A460
ROKU
Roku
2.8443 of 5 stars
$158.18
+0.4%
$156.17
-1.3%
+60.8%$23.48B$5.21B67.603,600
ZM
Zoom Communications
3.7503 of 5 stars
$104.83
-2.4%
$111.64
+6.5%
+17.5%$30.74B$4.93B15.397,438

Related Companies and Tools


This page (NYSE:TDOC) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners